Lilly/Isis Lung Cancer NDA Possible In 2003; Lymphoma Indication In Phase II
An NDA for the Isis drug 3521, licensed to Eli Lilly, could be submitted for non-small cell lung cancer by 2003.
An NDA for the Isis drug 3521, licensed to Eli Lilly, could be submitted for non-small cell lung cancer by 2003.